Why do the most recent NCCN guidelines (Version 4.2024, 05/17/24) omit the duration of ADT for high-risk prostate cancer patients?

No idea, but version 1.2025 (accessed 12/10/2024) now includes ADT duration for high-risk, which is 12-36 months, with notes indicating, "For high-risk and very-high-risk prostate cancer treated with combination EBRT brachytherapy, a shortened duration of ADT (12 months) can be considered." For high-risk patients not receiving a brachy boost, I would interpret the guidelines as being unchanged in regard to ADT duration.

There has been considerable discussion on whether or not brachytherapy shoul...